Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models

Clinical Cancer Research

Volumn 22, Issue 3, 2016, Pages 633-643

  Francis, David M ^a   Huang, Shyhmin ^a   Armstrong, Eric A ^a   Werner, Lauryn R ^a   Hullett, Craig ^a   Li, Chunrong ^a   Morris, Zachary S ^a   Swick, Adam D ^a   Kragh, Michael ^b   Lantto, Johan ^b   Kimple, Randall J ^a   Harari, Paul M ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b Symphogen AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; MONOCLONAL ANTIBODY; PAN HER INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL AGING; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CHEMORADIOTHERAPY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; FLOW CYTOMETRY; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; LUNG CANCER; LUNG CANCER CELL LINE; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOSENSITIZATION; RECEPTOR DOWN REGULATION; SINGLE DRUG DOSE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETICS; HEAD AND NECK TUMOR; LUNG TUMOR; METABOLISM; PATHOLOGY; RADIATION TOLERANCE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DNA REPAIR; ERBB RECEPTORS; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MICE; PROTEIN KINASE INHIBITORS; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84959018245     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1664     Document Type: Article

References (42)

1. Yarden Y, Sliwkowski MX. Untangling the erbb signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
2. Ang KK, Andratschke NH, Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 2004;58:959-65.
3. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of a431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 1983;80: 1337-41.
4. Morris ZS, Harari PM. Interaction of radiation therapy with molecular targeted agents. J Clin Oncol 2014;32:2886-93.
5. Huang S, Bock JM, Harari PM. Epidermal growth factor receptor blockade with c225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59: 1935-40.
6. Harari PM, Huang S. Combining egfr inhibitors with radiation or chemotherapy: Will preclinical studies predict clinical results? Int J Radiat Oncol Biol Phys 2004;58:976-83.
7. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
8. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27.
9. Arteaga CL. Egf receptor as a therapeutic target: Patient selection and mechanisms of resistance to receptor-targeted drugs. J Clin Oncol 2003;21: 289s-91s.
10. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, et al. Mechanisms of acquired resistance to cetuximab: Role of her (erbb) family members. Oncogene 2008;27:3944-56.
11. Vlacich G, Coffey RJ. Resistance to egfr-targeted therapy: A family affair. Cancer Cell 2011;20:423-25.
12. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase iii trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage iii to iv head and neck carcinoma: Rtog 0522. J Clin Oncol 2014;32:2940-50.
13. Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (concert-2): A randomised, controlled, open-label phase 2 trial. Lancet Oncol 2015;16:221-32.
14. Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, et al. Sym004: A novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010;70: 588-97.
15. Machiels JP, Specenier P, Krauss J, Dietz A, Kaminsky MC, Lalami Y, et al. A proof of concept trial of the anti-egfr antibodymixture sym004 in patients with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2015;76:13-20.
16. Jacobsen HJ, Poulsen TT, Dahlman A, Kjaer I, Koefoed K, Sen JW, et al. Panher, an antibody mixture simultaneously targeting egfr, her2 and her3 effectively overcomes tumor heterogeneity and plasticity. Clin Cancer Res 2015;21:4110-22.
17. Benavente S, Huang S, Armstrong EA, Chi A, Hsu K-T, Wheeler DL, et al. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 2009;15:1585-92.
18. Li J, Huang S, Armstrong EA, Fowler JF, Harari PM. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (vegfr2) blockade. Int J RadiatOncol Biol Phys 2005;62:1477-85.
19. Huang X, Darzynkiewicz Z. Cytometric assessment of histone h2ax phosphorylation: A reporter ofDNA damage. MethodsMol Biol 2006;314:73-80.
20. Smith J, Tho LM, Xu N, Gillespie DA. The atm-chk2 and atr-chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010;108:73-112.
21. Rodemann H, Dittmann K, Toulany M. Radiation-induced egfr-signaling and control of DNA-damage repair. Int J Radiat Biol 2007;83:781-91.
22. Yan Y, Hein AL, Greer PM, Wang Z, Kolb RH, Batra SK, et al. A novel function of her2/neu in the activation of g2/m checkpoint in response to gamma-irradiation. Oncogene 2015;34:2215-26.
23. Olive PL. Retention of gammah2ax foci as an indication of lethal DNA damage. Radiother Oncol 2011;101:18-23.
24. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, et al. ADNA damage checkpoint response in telomere-initiated senescence. Nature 2003;426:194-8.
25. Qu K, Xu X, Liu C, Wu Q, Wei J, Meng F, et al. Negative regulation of transcription factor foxm1 by p53 enhances oxaliplatin-induced senescence in hepatocellular carcinoma. Cancer Lett 2013;331:105-14.
26. Liu Q, Xu X, Zhao M, Wei Z, Li X, Zhang X, et al. Berberine induces senescence of human glioblastoma cells by downregulating the egfr-mekerk signaling pathway. Mol Cancer Ther 2015;14:355-63.
27. Kimple RJ, Harari PM, Torres AD, Yang RZ, Soriano BJ, Yu M, et al. Development and characterization of hpv-positive and hpv-negative head and neck squamous cell carcinoma tumorgrafts. Clin Cancer Res 2013; 19:855-64.
28. Harari PM, Wheeler DL, Grandis JR. Molecular target approaches in head and neck cancer: Epidermal growth factor receptor and beyond. Semin Radiat Oncol 2009;19:63-8.
29. Larbouret C, Gaborit N, Chardes T, Coelho M, Campigna E, Bascoul-Mollevi C, et al. In pancreatic carcinoma, dual egfr/her2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: Implication of receptors' down-regulation and dimers' disruption. Neoplasia 2012;14:121-30.
30. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, et al. A twoin-one antibody against her3 and egfr has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011;20:472-86.
31. McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, et al. Antitumor activity of a novel bispecific antibody that targets the erbb2/erbb3 oncogenic unit and inhibits heregulin-induced activation of erbb3. Mol Cancer Ther 2012;11:582-93.
32. Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, De Stanchina E, et al. Her2 amplification: A potential mechanism of acquired resistance to egfr inhibition in egfr-mutant lung cancers that lack the second-site egfrt790m mutation. Cancer Discov 2012;2:922-33.
33. Funayama T, Nakanishi T, Takahashi K, Taniguchi S, Takigawa M, Matsumura T. Overexpression of c-erbb-3 in various stages of human squamous cell carcinomas. Oncology 1998;55:161-7.
34. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. Met amplification leads to gefitinib resistance in lung cancer by activating erbb3 signaling. Science 2007;316:1039-43.
35. Tang Z, Du R, Jiang S, Wu C, Barkauskas DS, Richey J, et al. Dual met-egfr combinatorial inhibition against t790m-egfr-mediated erlotinib-resistant lung cancer. Br J Cancer 2008;99:911-22.
36. HuS, Fu W, Xu W, Yang Y, Cruz M, Berezov SD, et al. Four-in-one antibodies have superior cancer inhibitory activity against egfr, her2, her3, and vegf through disruption of her/met crosstalk. Cancer Res 2015;75:159-70.
37. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patientderived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012;9:338-50.
38. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517: 576-82.
39. Weng WK, Levy R. Twoimmunoglobulin g fragment c receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
40. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: A paradigm shift. J Natl Cancer Inst 2013;105:256-65.
41. DechantM,Weisner W, Berger S, PeippM, Beyer T, Schneider-Merck T, et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 2008;68: 4998-5003.
42. Chinnaiyan P, Allen GW, Harari PM. Radiation and new molecular agents, part ii: Targeting hdac, hsp90, igf-1r, pi3k, and ras. Semin Radiat Oncol 2006;16:59-64.